Evofem Biosciences (NASDAQ:EVFM – Get Free Report) and Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.
Earnings & Valuation
This table compares Evofem Biosciences and Chemomab Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evofem Biosciences | $11.39 million | 0.09 | $52.98 million | ($0.21) | -0.05 |
| Chemomab Therapeutics | N/A | N/A | -$24.22 million | ($0.90) | -1.33 |
Evofem Biosciences has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evofem Biosciences | 0 | 0 | 0 | 0 | 0.00 |
| Chemomab Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Chemomab Therapeutics has a consensus target price of $9.00, indicating a potential upside of 650.00%. Given Chemomab Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than Evofem Biosciences.
Volatility & Risk
Evofem Biosciences has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Profitability
This table compares Evofem Biosciences and Chemomab Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evofem Biosciences | -46.42% | -91.97% | -61.93% |
| Chemomab Therapeutics | N/A | -101.70% | -76.18% |
Insider & Institutional Ownership
0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Chemomab Therapeutics beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
